Lichong Xiaozheng Granules enhances cisplatin sensitivity of ovarian cancer xenografts in rats by regulating adenine nucleotide translocator 3-mediated mitochondrial apoptosis.
10.12122/j.issn.1673-4254.2025.11.03
- Author:
Yiliu CHEN
1
;
Min MA
1
;
Ran SU
1
;
Yinbin ZHU
1
;
Qing FENG
1
;
Jiali LUO
1
;
Weifeng FENG
2
;
Xianxin YAN
1
Author Information
1. College of Traditional Chinese Medicine, Jinan University, Guangzhou 510632, China.
2. First Affiliated Hospital,Jinan University, Guangzhou 510630, China.
- Publication Type:Journal Article
- Keywords:
Lichong Xiaozheng Granules;
adenine nucleotide translocator 3;
chemo-sensitization;
mitochondrial apoptosis;
ovarian cancer
- MeSH:
Animals;
Female;
Cisplatin/pharmacology*;
Ovarian Neoplasms/metabolism*;
Apoptosis/drug effects*;
Mitochondria/metabolism*;
Drugs, Chinese Herbal/pharmacology*;
Mice, Inbred BALB C;
Mice;
Rats;
Xenograft Model Antitumor Assays;
Humans;
Cell Line, Tumor;
Antineoplastic Agents/pharmacology*
- From:
Journal of Southern Medical University
2025;45(11):2309-2319
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the molecular mechanism by which Lichong Xiaozheng Granules (LCXZ) sensitize ovarian cancer to cisplatin (DDP) treatment.
METHODS:LC-MS analysis was used to identify the blood components of LCXZ after its administration in mice via gavage. In a BALB/c mouse model bearing subcutaneous ovarian cancer xenografts, the effects of daily gavage of distilled water (control group), intraperitoneal injection of DDP (5 mg/kg) once a week, or both DDP injection and daily LCXZK gavage (15 g/kg) on tumor growth were evaluated. Histopathological changes in the xenografts and kidneys were assessed with HE staining. RNA-seq was performed to identify the differentially expressed genes followed by KEGG pathway analysis. The changes in mitochondrial ultrastructure and expressions of mitochondrial apoptosis-related were examined with transmission electron microscopy and Western blotting.
RESULTS:A total of 218 blood-borne components of LCXZ were detected by LC-MS. In the tumor-bearing mice, treatments with DDP and DDP combined with LCXZ redcued the tumor volume by 60.3% and 72.6% compared with that in the control group, respectively. Transcriptomic analysis revealed significantly upregulated ANT3 expression in both the two treatment groups. Molecular docking indicated that the main active components of LCXZ were capable of binding to adenine nucleotide translocator 3 (ANT3) with binding energies below -6 kcal/mol. Transmission electron microscopy showed obvious mitochondrial swelling and outer-membrane damage in the tumor cells in DDP-treated mice, and these changes were more pronounced in the combined treatment group. The expression levels of BAX, ANT3, cleaved caspase-3 and cleaved caspase-9 were increased, whereas BCL-2 expression was decreased significantly in the tumor cells in both the DDP and DDP+LCXZ groups.
CONCLUSIONS:LCXZ enhances the therapeutic efficacy of cisplatin against ovarian cancer xenografts in mice by promoting mitochondrial dysfunction and activating apoptotic signaling pathways via upregulating ANT3.
